Regeneron/Bayer Bullish On Wet-AMD Drug But Commercial Success Is No Guarantee

Positive results of two Phase III studies show VEGF Trap-Eye candidate has potential for dosing every two months, but competing against Roche's Lucentis and off-label Avastin won't be easy.